RJFSA
BPMC

Raymond James Financial Services Advisors’s Blueprint Medicines BPMC Stock Holding History

Raymond James Financial Services Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.48M Buy
37,668
+4,671
+14% +$464K ﹤0.01% 1429
2024
Q2 		$3.56M Sell
32,997
-3,932
-11% -$394K 0.01% 1346
2024
Q1 		$3.5M Buy
36,929
+2,884
+8% +$247K 0.01% 1337
2023
Q4 		$3.14M Sell
34,045
-8,664
-20% -$561K 0.01% 1328
2023
Q3 		$2.14M Sell
42,709
-18,938
-31% -$1.01M ﹤0.01% 1467
2023
Q2 		$3.9M Buy
61,647
+26,292
+74% +$1.43M 0.01% 1156
2023
Q1 		$1.59M Sell
35,355
-298
-0.8% -$13.4K ﹤0.01% 1627
2022
Q4 		$1.56M Sell
35,653
-8,533
-19% -$409K ﹤0.01% 1585
2022
Q3 		$2.91M Buy
44,186
+3,211
+8% +$206K 0.01% 1220
2022
Q2 		$2.07M Buy
40,975
+7,601
+23% +$445K ﹤0.01% 1421
2022
Q1 		$2.13M Sell
33,374
-263
-0.8% -$18.9K ﹤0.01% 1449
2021
Q4 		$3.6M Buy
33,637
+5,969
+22% +$624K 0.01% 1184
2021
Q3 		$2.85M Buy
27,668
+7,281
+36% +$678K 0.01% 1280
2021
Q2 		$1.79M Buy
20,387
+525
+3% +$48.1K ﹤0.01% 1537
2021
Q1 		$1.93M Sell
19,862
-6,787
-25% -$678K ﹤0.01% 1424
2020
Q4 		$2.99M Sell
26,649
-7,925
-23% -$835K 0.01% 1071
2020
Q3 		$3.21M Sell
34,574
-3,884
-10% -$299K 0.01% 948
2020
Q2 		$3M Sell
38,458
-1,486
-4% -$101K 0.01% 935
2020
Q1 		$2.34M Buy
39,944
+19,120
+92% +$1.23M 0.01% 822
2019
Q4 		$1.67M Buy
20,824
+18,046
+650% +$1.35M 0.01% 1250
2019
Q3 		$204K Sell
2,778
-403
-13% -$34.8K ﹤0.01% 2495
2019
Q2 		$300K Buy
+3,181
New +$263K ﹤0.01% 2275
2017
Q3 		– Sell
-10,360
Closed -$525K – 2570
2017
Q2 		$525K Buy
+10,360
New +$440K ﹤0.01% 1647

Other funds holding BPMC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James Financial Services Advisors's BPMC Position: Q3 2024 in Review

Raymond James Financial Services Advisors increased its Blueprint Medicines (BPMC) stake by 14% in Q3 2024, buying an estimated $464K and bringing the position to 37,668 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1429.

Raymond James Financial Services Advisors first reported a position in BPMC in Q2 2017 and has held it in 23 quarters since. The position peaked at $3.9M in Q2 2023. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • Raymond James Financial Services Advisors held 37,668 shares of Blueprint Medicines worth $3.48M as of Q3 2024.
  • Raymond James Financial Services Advisors bought 4,671 Blueprint Medicines shares in Q3 2024, an estimated $464K.
  • Blueprint Medicines made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1429 holding.
  • Raymond James Financial Services Advisors first reported a position in Blueprint Medicines in Q2 2017 and has held it in 23 quarters since.
  • Raymond James Financial Services Advisors's Blueprint Medicines position peaked at $3.9M in Q2 2023.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.